Poor
Partially Aligned
Patient Risk:
Moderate
Summary
The AI response makes many general statements about combining antivirals and kidney-risk/monitoring that are not supported by the provided label excerpts. The label provided includes only limited interaction information (probenecid with IV acyclovir) and does not support most specific claims about combining acyclovir with other antivirals (e.g., influenza/HIV pairings, typical outpatient use, or safety dependence on dehydration/kidney-risk medicines).
Category Scores
Accurate Statements
Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.
Section 4 — “Acyclovir is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir.”
In patients with renal impairment, acyclovir dosing should be modified and dose adjustment is recommended for reduced renal function.
Section 2 — “In patients with renal impairment, the dose... should be modified as shown in Table 3.” and Section 12 — “A dosage adjustment is recommended for patients with reduced renal function...”
Coadministration of probenecid with intravenous acyclovir increases acyclovir half-life and reduces urinary excretion/renal clearance.
Section 7 — “Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life... AUrinary excretion and renal clearance were correspondingly reduced.”
Renal failure has been observed with acyclovir therapy.
Section 5 — “Renal failure, in some cases resulting in death, has been observed with acyclovir therapy...”
Nausea and/or vomiting are among the most frequent adverse events reported in genital herpes studies.
Section 6 — “...treatment of genital herpes with acyclovir 200 mg... were nausea and/or vomiting... (2.7%).”
Unsupported Statements
Combining antivirals can increase side effects, especially kidney-related effects.
The provided label excerpts do not state that combining acyclovir with other antivirals increases side effects; only a specific interaction is described for probenecid with IV acyclovir.
The safest answer for whether to combine acyclovir with other antivirals depends on the specific medicines involved and the patient's kidney function.
The label supports renal impairment dose adjustment but does not provide guidance that the decision to combine antivirals depends on specific drugs/kidney function.
In outpatient situations for herpes infections, acyclovir is often used alone rather than paired with another herpes antiviral unless a clinician has a specific reason.
The provided label excerpts do not discuss typical outpatient combination practices or monotherapy vs combination use.
A main practical concern with acyclovir combinations is additive risk of kidney strain because acyclovir can affect renal function.
The label does not discuss additive kidney risk from combining with other antivirals.
Other antivirals that can stress the kidneys may raise risk if used together with acyclovir.
No label support is provided for interactions between acyclovir and other antivirals or for “kidney-stress” risk from specific antivirals.
Risk from combining antivirals is higher if the patient has chronic kidney disease.
The label excerpts indicate renal impairment requires dose modification, but they do not state increased risk specifically from combining antivirals.
Risk from combining antivirals is higher if the patient is dehydrated.
The provided label excerpts do not mention dehydration as a risk factor.
Risk from combining antivirals is higher if the patient takes other kidney-risk medicines (examples: some NSAIDs, certain antibiotics, or diuretics).
The provided label excerpts do not list these as interacting/kidney-risk medicines with acyclovir.
Combining antivirals is not automatically forbidden.
The label excerpt set includes contraindication only for hypersensitivity; it does not address whether combining with other antivirals is forbidden or allowed.
Combining antivirals can require dose adjustment and monitoring.
The label supports dose adjustment in renal impairment generally, but does not specifically state that antiviral combinations require dose adjustment/monitoring.
Acyclovir with valacyclovir or famciclovir is usually not standard practice.
The provided label excerpts do not discuss standard practice regarding these combinations.
There may be fewer direct overlaps when acyclovir is combined with antivirals for influenza or HIV.
The label excerpts do not discuss influenza or HIV antiviral combinations with acyclovir.
If using oral or IV acyclovir, the route affects how dosing and safety are determined for the combination.
The provided label excerpts do not address route-specific combination decision-making; the only interaction excerpt relates to IV acyclovir with probenecid.
Possible kidney problems after starting multiple antivirals can include decreased urination, swelling, or unusual fatigue.
While renal failure is described, the specific symptom examples (decreased urination, swelling, unusual fatigue) are not supported in the provided label excerpts.
Possible kidney problems after starting multiple antivirals can require prompt medical advice.
The label excerpt set does not provide such combination-specific patient advice for kidney symptoms.
Possible adverse effects to seek medical advice for include confusion or severe dizziness.
The label excerpts list hallucinations and somnolence, but do not specifically advise seeking medical advice for confusion or severe dizziness.
Possible adverse effects to seek medical advice for include severe nausea/vomiting or worsening dehydration.
The label excerpts mention nausea/vomiting as common events, but do not provide advice about seeking medical care for severe nausea/vomiting or worsening dehydration.
Possible allergic reactions to seek medical advice for include a rash that spreads or breathing trouble.
The label excerpts provided do not include these specific symptom triggers or patient counseling statements.
If a patient is already taking two antivirals and feels unwell, they should call their prescriber or pharmacist promptly.
The provided label excerpts do not include this specific counseling instruction tied to taking two antivirals.
Contradictions
Important Omissions
Boxed warning/major safety framing: the provided label excerpts include serious warnings (renal failure; TTP/HUS) but the AI response does not mention TTP/HUS or that renal failure can result in death.
Importance:
Moderate
Contraindication detail: the AI response does not clearly restate the specific contraindication for hypersensitivity to acyclovir or valacyclovir (though it is included in the evaluation as an accurate statement, the overall response is mostly about combinations and does not anchor on this contraindication).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most safety-related content in the AI response is speculative or not supported by the provided label excerpts, particularly regarding combination-specific kidney risk, dehydration, and specific symptom- and action-trigger advice.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
The response contains many claims about combining acyclovir with other antivirals and kidney-risk/monitoring that are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported facts: indications; renal impairment dose adjustment; the specific contraindication for hypersensitivity to acyclovir/valacyclovir; and the label-described interaction (probenecid with IV acyclovir). Avoid speculative combination-specific risks and unlabelled symptom counseling triggers unless explicitly supported in the provided prescribing information.